EIK1003-001 (IMP1734-101): A First-in-Human, Phase 1/2, Open-Label, Multicenter, Dose-Escalation, Dose-Optimization, and Dose-Expansion Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Ph

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Alejandro Recio Boiles
Sponsor
Eikon Therapeutics
Unit
Cancer Center Division